Intravacc launches phase I clinical trial of Avacc 10, an intranasal subunit booster vaccine for SARS-CoV-2
Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023
Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023